Prognostic analysis for patients with Waldenström's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with Waldenström's macroglobulinemia (WM), a condition characterized by lymphoplasmocytic infiltration and high levels of monoclonal immunoglobulin M (IgM). It aims to improve prognostic assessments for asymptomatic patients by evaluating various clinical and molecular factors, including serum albumin and free light chain concentrations. The study will follow patients until at least 2024 to gather comprehensive data on their disease progression and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with WM, fulfilling the diagnostic criteria defined at the 2nd Workshop on WM.
* Patient in whom follow-up is available until at least 01/01/2020. Each participating center should not enroll more 10% of patients lost to follow-up.
* Patient for whom a minimum annual follow-up is planned until 2024.
* Having given their consent for this study

Exclusion Criteria:

* Patient with other chronic lymphoid malignancy. Special attention will be paid to exclude other lymphoplasmacytic proliferations, especially marginal zone lymphoma.
* Patient with histological transformation in a diffuse large B-cell lymphoma or any other lymphoma at the time of the initiation of the 1st treatment.
* No consent for this study.

Where it's running

• LILLE GHICL - Hôpital Saint Vincent de Paul
  Lille, France Recruiting
• AMIENS - CH Amiens Picardie Site Sud
  Amiens, France Not yet recruiting
• Angers Chu
  Angers, France Not yet recruiting
• Institut Bergonie
  Bordeaux, France Not yet recruiting
• Clermont-Ferrand - Chu Estaing
  Clermont-Ferrand, France Not yet recruiting
• Le Mans CH
  Le Mans, France Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Measuring circulating tumor DNA to predict outcomes after six months of treatment in Waldenström macroglobulinemia

  This will test whether measuring circulating tumor DNA after six months of treatment helps predict outcomes for people with Waldenström macroglobulinemia.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT04893564

• Tagraxofusp and venetoclax in newly diagnosed BPDCN

  This trial tests whether combining tagraxofusp with venetoclax can produce higher complete remissions in adults with newly diagnosed BPDCN.

  Recruiting at 8 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 33 other locations · NCT07007052

• Observational study of older patients with acute myeloid leukemia receiving intensive treatment

  This study looks at older patients with acute myeloid leukemia to see how well intensive treatment works for them and what factors might affect their recovery and survival.

  Recruiting at 27 sites French Innovative Leukemia Organisation · Angers and 26 other locations · NCT06891144

• Observational study on the use of Ivosidenib for patients with Acute Myeloid Leukemia in France

  This study looks at how well a drug called Ivosidenib works for people in France with acute myeloid leukemia who have a specific gene mutation, to see if it helps them feel better or respond to treatment.

  Recruiting at 6 sites French Innovative Leukemia Organisation · Amiens and 20 other locations · NCT06377579

• Treatment for Richter Syndrome using Glofitamab with Rituximab or Obinutuzumab plus CHOP

  This study is testing if a new treatment combining Glofitamab with Rituximab or Obinutuzumab and CHOP chemotherapy can help people with untreated Richter Syndrome feel better.

  Recruiting at 6 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 22 other locations · NCT06186648

• Combining oral azacitidine with gilteritinib for treating relapsed FLT3-mutated acute myeloid leukemia

  This study is testing if adding an oral medication called azacitidine to gilteritinib can help adults with relapsed FLT3-mutated acute myeloid leukemia feel better and live longer.

  Recruiting at 3 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 19 other locations · NCT06022003

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.